NVDAMillionaire
Posted - 2 days ago
$GKOS Glaukos Corporation (GKOS): Pioneering a New Frontier in Ophthalmic Treatments https://beyondspx.com/article/glaukos-nasdaq-gkos-a-promising-ophthalmic-innovator-poised-for-growth
Rmimidear
Posted - 4 days ago
$GKOS Glaukos’ focus on ophthalmic treatments positions it as a leader in innovative solutions for eye health!
TickerDD_com
Posted - 1 week ago
$GKOS How much is GKOS Shorted? What is Short Interest for GKOS? As of 10-31-2024
https://youtu.be/UJ7OjGN-Vuw
ChristaBoarts
Posted - 1 week ago
$GKOS IBO’s market reach is expanding with every new patent issued in biopharma.
IN0V8
Posted - 2 weeks ago
$GKOS Opportunity JP Morgan raises target price to $145 from $130 Wells Fargo raises target price to $145 from $135
DonCorleone77
Posted - 2 weeks ago
$GKOS Glaukos raises FY24 revenue $377M-$379M from $370M-$376M Consensus $373.76M.
DonCorleone77
Posted - 2 weeks ago
$GKOS Glaukos reports Q3 adjusted EPS (28c), consensus (48c) Reports Q3 revenue $96.7M, consensus $91.49M. "Our record third quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
Estimize
Posted - 2 weeks ago
$GKOS reports after the close, Estimize Consensus +0.01 EPS and +0.73M Revs compared to WS
http://www.estimize.com/gkos/fq3-2024?utm_conten
insiderbuyingselling
Posted - 2 weeks ago
$GKOS new insider selling: 2275 shares. http://insiderbuyingselling.com/?t=GKOS
ChessGM
Posted - 10/29/24
$GKOS Heads up alert! Only one day until Upcoming Earnings on 10/30/2024 Bullish (8.4) Glaukos Corporation (GKOS) is currently positioned favorably within the ophthalmic pharmaceutical and medical technology sector, bolstered by recent advancements in its product pipeline, particularly with the successful Phase 3 trial for its keratoconus medication, Epioxa. The company has reported a significant rise in stock value, with an impressive 59.2% increase year-to-date, driven by strong demand for its therapies and expansion into new markets. Key financial metrics indicate a favorable outlook: the company has been consistently improving its earnings per share (EPS), with analysts forecasting continued growth, supported by a robust development pipeline. The price-to-earnings (P/E) ratio is competitive compared to industry peers, which typically range higher, reflecting investor confidence in GKOS's innovative solutions. Revenue forecasts remain optimistic, particularly with anticipated FDA approval for Epioxa, which could further enhance market penetration and revenue streams. Looking ahead, Glaukos is scheduled to release its third-quarter financial results on November 4, 2024. Analysts expect the company to report earnings that exceed consensus estimates, given the positive trajectory established by recent trial outcomes and ongoing demand for its products. Historical performance has demonstrated the company’s ability to generate strong results, often beating analyst expectations, which could lead to further upward momentum for the stock. The upcoming earnings call is likely to attract significant attention from investors and analysts alike, as insights into the company's operational performance and strategic direction will be closely scrutinized. Overall, the stock's current trajectory, combined with its promising product pipeline and market position, suggests a bullish outlook in the near term. - Funds were net buyers of $GKOS during the previous reporting quarter. - Top 5 funds with large holdings in $GKOS: * Brown Capital Management $225MM. CGMRank: 80% * Gilder Gagnon Howe & Co LLC $75MM. CGMRank: 77% * Point72 Asset Management LP $67MM. New position. CGMRank: 81% * Riverbridge Partners LLC $58MM. CGMRank: 66% * Summit Partners Public Asset Management LLC $49MM. New position. CGMRank: 56% - Last 10 days performance: 1% - Last 30 days performance: 5% - Last 90 days performance: 14% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.
Estimize
Posted - 10/28/24
Estimize revenue expectations are 1.13% higher than that of Wall Street for $GKOS Q3 [Reporting 11/04 AMC]
http://www.estimize.com/intro/gk
FridayGuy
Posted - 10/24/24
$GKOS X.COM Grok AI shows this stock as the best biotech stock in Russell 2000 with best upside potential; I just bought Calls; I'm a newbie here in this group...nice to join
evanmedeiros
Posted - 1 month ago
Looing for a tight consolidation? Check out GKOS on the daily. Full month in a 3.50% low to high range. Showing up on our TC20000 ultimate consolidation stock screener today (no position) $GKOS
DonCorleone77
Posted - 1 month ago
$GKOS Glaukos says Epioxa Phase 3 confirmatory trial meets primary endpoint Glaukos Corporation announced that the second Phase 3 confirmatory pivotal trial for Epioxa, its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, successfully met the study's pre-specified primary efficacy endpoint, demonstrating a clinically relevant and statistically significant improvement in maximum corneal curvature at 12 months from baseline between the Epioxa treated arm and the sham/placebo-controlled arm. Kmax is a U.S. FDA-accepted primary efficacy outcome for keratoconus pivotal trials and an objective measurement of the steepest corneal curvature based on corneal topography, where an increasing Kmax denotes corneal steepening and keratoconus disease progression. "We are excited to announce these positive Phase 3 confirmatory results that met the study's primary efficacy endpoint and once again demonstrated the potential of Epioxa to halt or reduce the advancement of keratoconus, a progressive, sight-threatening corneal disease. These results further underscore our view that Epioxa may provide the ophthalmic community and keratoconus patients with the first FDA-approved, non-invasive, bio-activated drug treatment alternative designed to reduce procedure time, improve patient comfort and shorten recovery time," said Thomas Burns, Glaukos chairman and chief executive officer. "We appreciate the commitment and dedication of the clinical investigators, who play a vital role in bringing new innovations to patients suffering from keratoconus and at risk for significant vision loss. We expect these data to support our anticipated NDA targeted for FDA submission by the end of this year."
BioTuesdays
Posted - 1 month ago
Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation, enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release implants of targeted APIs for glaucoma and retinal diseases. $GKOS https://biotuesdays.com/2024/10/15/ripple-and-glaukos-ink-evaluation-and-licensing-agreements/
IN0V8
Posted - 1 month ago
$GKOS Opportunity Truist Securities raises target price to $152 from $145
Americanbulls
Posted - 1 month ago
$GKOS apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=GKOS
JFDI
Posted - 1 month ago
$GKOS stair stepping
IN0V8
Posted - 08/27/24
$GKOS Needham raises target price to $149 from $137
PenkeTrading
Posted - 08/23/24
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Glaukos Corp. Is that bullish or bearish? $GKOS #GKOS #nyse #tradingsignals #technicalanalysis
LudicrousReturns
Posted - 08/22/24
4 Stocks that hit buy triggers on Monday: $EOSE, $NOVA, $KRNT, $GKOS. My apologies that I didn’t get the message out sooner on EOSE to share the wealth. EOSE is manufactures batteries for energy storage for the utilities. It is a huge future growth area, as the electrical infrastructure is trying to expand capacity for EVs and artificial intelligence. More specifically, the expansion in capacity is also focused on re-newable energy, which really needs places to store clean energy generation so that it can be put to use when the sun is not shining or the wind is not blowing. I wouldn’t worry that the 26% pop from yesterday was missed, my model predicts plenty of growth ahead for this new opportunity growth stock.
fda_tracker
Posted - 3 months ago
$GKOS Phase 2 trial w/est Aug completion date NCT06152861: https://www.clinicaltrials.gov/study/NCT06152861 Trial Tracker: https://www.fdatracker.com/trial-tracker/
Doozio
Posted - 3 months ago
$GKOS Thursday 🐑 low in 🧠⏰?
Stocksrunner
Posted - 3 months ago
Comeback Kings: Check out these impressive rebounders: $ABUS, $GKOS, $SPWR, $NVAX, $ASTS! These companies showed incredible resilience today, bouncing back after hitting lows earlier in the trading session. It’s always thrilling to see such strong recoveries! Let’s keep this energy going into tomorrow! 🚀💪
IN0V8
Posted - 3 months ago
$GKOS Opportunity Jefferies raises target price to $145 from $125 JP Morgan raises target price to $130 from $110 Needham raises target price to $137 from $131 Piper Sandler raises target price to $140 from $110 Truist Securities raises target price to $145 from $141 Wells Fargo raises target price to $135 from $120
erevnon
Posted - 3 months ago
Needham maintains Glaukos $GKOS at Buy and raises the price target from $131 to https://marketsblock.com/stock-upgrades-and-downgrades/
epsguid
Posted - 07/31/24
$GKOS reported a loss of $0.52, consensus was ($0.52), Earnings Whisper was ($0.50) via @eWhispers #whispermiss http://eps.sh/d/gkos
DonCorleone77
Posted - 07/31/24
$GKOS Glaukos raises FY24 revenue view to $370M-$376M from $357M-$365M Consensus $363.02M.
DonCorleone77
Posted - 07/31/24
$GKOS Glaukos reports Q2 adjusted EPS (52c), consensus (51c) Reports Q2 revenue $95.7M, consensus $88.89M. "Our record second quarter results reflect successful global execution of our key strategic plans and growing momentum in our business," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
